James reimann, Ph.D.

Independent Leadership Coach and Strategic Statistical Consultant

CoCreative Insights

In July 2025 James completed a 30-year career as a Biostatistician and Data Science leader at Genentech/Roche to start his own company, CoCreative Insights, which combines two strong passions of human personal development and the development of better medicines to treat cancer. 

Professional coaching spans both professional and personal domains, and includes executive coaching, leadership & career coaching, and life transitions coaching. Statistical consulting includes advising on CDPs for Oncology developmental therapeutics, serving as independent statistician on iDMCs for oncology studies, and advising companies approaching key Health Authority interactions. 

James was raised in South Australia and completed his undergraduate studies in Statistics and Applied Mathematics at the University of Adelaide.  He came to California in 1990 to pursue PhD studies in Statistics at the University of California at Berkeley, during which he first worked for Genentech as Summer Intern in Nonclinical Statistics.  James joined Genentech in 1994 and spent his first 5 years supporting Clinical Pharmacology and Early-Development for experimental therapies for various non-Oncology therapeutic areas. 

James joined the Avastin project in 2000 as was responsible for the first Phase III study of Avastin in breast cancer and later served as the Development filing team leader for the US BLA submission in colorectal cancer.  He then led the biostatistics group supporting the HER projects (Herceptin, Perjeta, and Tarceva) including the US approval for Tarceva in lung cancer.  He then took on positions of increasing responsibility, including Development Team Leader for Herceptin, Genentech head for Avastin Biostatistics, and Global Head of Oncology Biostatistics. Later his remit broadened to include the Patient-Centered Outcome Research, group which develops, applies, and analyzes patient-centered endpoints in clinical trials across all disease areas at Roche. 

After 20 years working in oncology clinical research, in 2020 James moved to a completely different area of quantitative science and took on the role of head of Data Strategy & Delivery, in order to create a strategic, end-to-end clinical data business that balances primary and secondary data use.